

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human mon...
Q4 2026
Sep 16, 2026
Q3 2026
May 12, 2026
Q2 2026
Feb 12, 2026
Q1 2026
Nov 6, 2025
FY 2025
Sep 17, 2025